Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT).

PubWeight™: 4.12‹?› | Rank: Top 1%

🔗 View Article (PMID 15692973)

Published in Arthritis Rheum on February 01, 2005

Authors

Désirée van der Heijde1, Ben Dijkmans, Piet Geusens, Joachim Sieper, Kimberly DeWoody, Paul Williamson, Jürgen Braun, Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy Study Group

Author Affiliations

1: University Hospital Maastricht, Maastricht, The Netherlands. dhe@sint.azm.nl <dhe@sint.azm.nl>

Articles citing this

(truncated to the top 100)

Randomized controlled trial of adalimumab in patients with nonpsoriatic peripheral spondyloarthritis. Arthritis Rheumatol (2015) 4.41

ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis (2005) 4.31

A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis (2013) 3.43

Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1). Ann Rheum Dis (2012) 3.00

The impact of tumor necrosis factor α inhibitors on radiographic progression in ankylosing spondylitis. Arthritis Rheum (2013) 2.40

First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis. Ann Rheum Dis (2005) 2.21

Monitoring of nonsteroidal immunosuppressive drugs in patients with lung disease and lung transplant recipients: American College of Chest Physicians evidence-based clinical practice guidelines. Chest (2012) 2.12

TNFalpha blockade in human diseases: an overview of efficacy and safety. Clin Immunol (2007) 1.85

Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study. Ann Rheum Dis (2013) 1.81

Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005. Ann Rheum Dis (2005) 1.77

Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases. Ann Rheum Dis (2009) 1.71

Current evidence for the management of ankylosing spondylitis: a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis. Ann Rheum Dis (2005) 1.70

The relationship between inflammation and new bone formation in patients with ankylosing spondylitis. Arthritis Res Ther (2008) 1.56

Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial. Ann Rheum Dis (2008) 1.49

Double-blind, placebo-controlled randomized trial with adalimumab for treatment of juvenile onset ankylosing spondylitis (JoAS): significant short term improvement. Arthritis Res Ther (2012) 1.46

Effects of etanercept versus sulfasalazine in early axial spondyloarthritis on active inflammatory lesions as detected by whole-body MRI (ESTHER): a 48-week randomised controlled trial. Ann Rheum Dis (2011) 1.46

Inflammatory biomarkers, disease activity and spinal disease measures in patients with ankylosing spondylitis after treatment with infliximab. Ann Rheum Dis (2007) 1.44

The prevalence and clinical characteristics of nonradiographic axial spondyloarthritis among patients with inflammatory back pain in rheumatology practices: a multinational, multicenter study. Arthritis Res Ther (2016) 1.39

Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases. Arthritis Res Ther (2011) 1.37

Decreased clinical response to infliximab in ankylosing spondylitis is correlated with anti-infliximab formation. Ann Rheum Dis (2007) 1.37

Predicting the outcome of ankylosing spondylitis therapy. Ann Rheum Dis (2011) 1.35

Ankylosing spondylitis: recent breakthroughs in diagnosis and treatment. J Can Chiropr Assoc (2007) 1.34

[Recommendations for the management of ankylosing spodylitis after ASAS/EULAR. Evaluation in the German language area]. Z Rheumatol (2006) 1.18

Relationship between active inflammatory lesions in the spine and sacroiliac joints and new development of chronic lesions on whole-body MRI in early axial spondyloarthritis: results of the ESTHER trial at week 48. Ann Rheum Dis (2011) 1.18

Effects of infliximab on markers of inflammation and bone turnover and associations with bone mineral density in patients with ankylosing spondylitis. Ann Rheum Dis (2008) 1.18

Structural damage in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: traditional views, novel insights gained from TNF blockade, and concepts for the future. Arthritis Res Ther (2011) 1.17

Prevalence of self-reported spondyloarthritis features in a cohort of patients with inflammatory bowel disease. Can J Gastroenterol (2013) 1.09

How early should ankylosing spondylitis be treated with tumour necrosis factor blockers? Ann Rheum Dis (2005) 1.09

Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study. Ann Rheum Dis (2016) 1.08

Treatment of ankylosing spondylitis with TNF blockers: a meta-analysis. Rheumatol Int (2013) 1.06

Canadian Association of Gastroenterology Clinical Practice Guidelines: The use of tumour necrosis factor-alpha antagonist therapy in Crohn's disease. Can J Gastroenterol (2009) 1.06

Ankylosing spondylitis is linked to Klebsiella--the evidence. Clin Rheumatol (2006) 1.06

Low doses of etanercept can be effective in ankylosing spondylitis patients who achieve remission of the disease. Clin Rheumatol (2011) 1.04

Assessment of short-term symptomatic efficacy of tocilizumab in ankylosing spondylitis: results of randomised, placebo-controlled trials. Ann Rheum Dis (2013) 1.03

Is extrapolation of the safety and efficacy data in one indication to another appropriate for biosimilars? AAPS J (2013) 1.02

Diagnosis delay in patients with ankylosing spondylitis: possible reasons and proposals for new diagnostic criteria. Clin Rheumatol (2007) 1.01

Predictors of response to anti-TNF therapy in ankylosing spondylitis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford) (2009) 1.01

Inefficacy of infliximab in ankylosing spondylitis is correlated with antibody formation. Ann Rheum Dis (2007) 0.99

Infliximab: 12 years of experience. Arthritis Res Ther (2011) 0.99

Early response to adalimumab predicts long-term remission through 5 years of treatment in patients with ankylosing spondylitis. Ann Rheum Dis (2011) 0.99

A systematic MEDLINE analysis of therapeutic approaches in ankylosing spondylitis. Rheumatol Int (2009) 0.98

Management and evaluation of extra-articular manifestations in spondyloarthritis. Ther Adv Musculoskelet Dis (2012) 0.97

Disease modification in ankylosing spondylitis. Nat Rev Rheumatol (2010) 0.96

Comparable long-term efficacy, as assessed by patient-reported outcomes, safety and pharmacokinetics, of CT-P13 and reference infliximab in patients with ankylosing spondylitis: 54-week results from the randomized, parallel-group PLANETAS study. Arthritis Res Ther (2016) 0.95

Diagnosis and management of ankylosing spondylitis. BMJ (2006) 0.94

Body mass index influences the response to infliximab in ankylosing spondylitis. Arthritis Res Ther (2012) 0.94

Efficacy of etanercept on rheumatic signs and pulmonary function tests in advanced ankylosing spondylitis: results of a randomised double-blind placebo-controlled study (SPINE). Ann Rheum Dis (2011) 0.93

Update on the treatment of ankylosing spondylitis. Ther Clin Risk Manag (2007) 0.93

The impact of infliximab treatment on quality of life in patients with inflammatory rheumatic diseases. Arthritis Res Ther (2007) 0.92

Treating axial and peripheral spondyloarthritis, including psoriatic arthritis, to target: results of a systematic literature search to support an international treat-to-target recommendation in spondyloarthritis. Ann Rheum Dis (2013) 0.91

Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy. Arthritis Res Ther (2010) 0.91

Physical function, disease activity, and health-related quality-of-life outcomes after 3 years of adalimumab treatment in patients with ankylosing spondylitis. Arthritis Res Ther (2009) 0.91

Measuring disease activity in psoriatic arthritis. Int J Rheumatol (2012) 0.90

Maintenance of biologic-free remission with naproxen or no treatment in patients with early, active axial spondyloarthritis: results from a 6-month, randomised, open-label follow-up study, INFAST Part 2. Ann Rheum Dis (2013) 0.90

Adalimumab effectively reduces the signs and symptoms of active ankylosing spondylitis in patients with total spinal ankylosis. Ann Rheum Dis (2007) 0.89

Axial spondyloarthritis: is there a treatment of choice? Ther Adv Musculoskelet Dis (2013) 0.89

Infliximab in ankylosing spondylitis: alone or in combination with methotrexate? A pharmacokinetic comparative study. Arthritis Res Ther (2011) 0.89

A 2-year comparative open label randomized study of efficacy and safety of etanercept and infliximab in patients with ankylosing spondylitis. Rheumatol Int (2009) 0.89

Report of 12 cases of ankylosing spondylitis patients treated with Tripterygium wilfordii. Clin Rheumatol (2010) 0.89

New evidence on the management of spondyloarthritis. Nat Rev Rheumatol (2016) 0.87

Anti-TNF therapy in the treatment of ankylosing spondylitis: the Finnish experience. Clin Rheumatol (2007) 0.87

Adalimumab in the treatment of arthritis. Ther Clin Risk Manag (2007) 0.86

Advances in managing ankylosing spondylitis. F1000Prime Rep (2014) 0.85

Impact of three anti-TNFalpha biologics on existing and emergent autoimmunity in rheumatoid arthritis and spondylarthropathy patients. J Clin Immunol (2008) 0.85

Multicenter validation of the value of BASFI and BASDAI in Chinese ankylosing spondylitis and undifferentiated spondyloarthropathy patients. Rheumatol Int (2009) 0.85

[Outcome parameters in ankylosing spondylitis]. Z Rheumatol (2006) 0.85

Effects of physical therapy for the management of patients with ankylosing spondylitis in the biological era. Clin Rheumatol (2014) 0.84

Patients with ankylosing spondylitis have increased sick leave--a registry-based case-control study over 7 yrs. Rheumatology (Oxford) (2009) 0.84

Rate and Predisposing Factors for Sacroiliac Joint Radiographic Progression After a Two-Year Follow-up Period in Recent-Onset Spondyloarthritis. Arthritis Rheumatol (2016) 0.82

Simultaneous multioutcome synthesis and mapping of treatment effects to a common scale. Value Health (2014) 0.82

A multicenter, open-label, efficacy, pharmacokinetic, and safety study of adalimumab in Japanese patients with ankylosing spondylitis. Mod Rheumatol (2011) 0.82

Psychometric characteristics of the short form 36 health survey and functional assessment of chronic illness Therapy-Fatigue subscale for patients with ankylosing spondylitis. Health Qual Life Outcomes (2011) 0.81

Comparison of tuberculosis incidence in ankylosing spondylitis and rheumatoid arthritis during tumor necrosis factor inhibitor treatment in an intermediate burden area. Clin Rheumatol (2013) 0.81

Outcomes in ankylosing spondylitis: what makes the assessment of treatment effects in ankylosing spondylitis different? Ann Rheum Dis (2006) 0.81

Reproducibility of the Bath Ankylosing Spondylitis Indices of disease activity (BASDAI), functional status (BASFI) and overall well-being (BAS-G) in anti-tumour necrosis factor-treated spondyloarthropathy patients. Clin Rheumatol (2010) 0.80

Effectiveness of adalimumab in treating patients with ankylosing spondylitis associated with enthesitis and peripheral arthritis. Arthritis Res Ther (2010) 0.80

Infliximab dose reduction sustains the clinical treatment effect in active HLAB27 positive ankylosing spondylitis: a two-year pilot study. Mediators Inflamm (2013) 0.80

Scintigraphic detection of TNF-driven inflammation by radiolabelled certolizumab pegol in patients with rheumatoid arthritis and spondyloarthritis. RMD Open (2016) 0.80

Comparative Effectiveness of Biologic Therapy Regimens for Ankylosing Spondylitis: A Systematic Review and a Network Meta-Analysis. Medicine (Baltimore) (2016) 0.80

Biological therapies for the treatment of juvenile idiopathic arthritis: Lessons from the adult and pediatric experiences. Biologics (2008) 0.80

Long-term safety and efficacy of infliximab for the treatment of ankylosing spondylitis. Ther Clin Risk Manag (2015) 0.80

Long-term efficiency of infliximab in patients with ankylosing spondylitis: real life data confirm the potential for dose reduction. RMD Open (2016) 0.79

Biological therapies for spondyloarthritis. Ther Adv Musculoskelet Dis (2014) 0.79

Response to one infusion predicts subsequent improvement as well as the rate of relapse of ankylosing spondylitis infused with three pulses of infliximab. Clin Rheumatol (2006) 0.78

[Early diagnosis of spondyloarthritis with special attention to the axial forms]. Z Rheumatol (2005) 0.78

Screening and referral for axial spondyloarthritis--need of the hour. Clin Rheumatol (2015) 0.78

Spontaneous, drug-induced, and drug-free remission in peripheral and axial spondyloarthritis. Best Pract Res Clin Rheumatol (2014) 0.78

Does the reason for discontinuation of a first TNF inhibitor influence the effectiveness of a second TNF inhibitor in axial spondyloarthritis? Results from the Swiss Clinical Quality Management Cohort. Arthritis Res Ther (2016) 0.77

Short term in-patient rehabilitation in axial spondyloarthritis - the results of a 2-week program performed in daily clinical practice. BMC Res Notes (2013) 0.77

[German Society for Rheumatology S3 guidelines on axial spondyloarthritis including Bechterew's disease and early forms: 8.4 Pharmaceutical therapy, 8.5 Evaluation of therapy success of pharmaceutical measures]. Z Rheumatol (2014) 0.77

Thoughts and perceptions of ankylosing spondylitis patients with regard to TNF inhibitors. Rheumatol Int (2013) 0.77

Old and new treatment targets in axial spondyloarthritis. RMD Open (2015) 0.77

A survey of inclusion of the time element when reporting adverse effects in randomised controlled trials of cyclo-oxygenase-2 and tumour necrosis factor alpha inhibitors. Ann Rheum Dis (2006) 0.77

Ankylosing spondylitis in Ireland: patient access and response to TNF-α blockers. Rheumatol Int (2011) 0.77

Predictors of response to TNF antagonists in patients with ankylosing spondylitis and psoriatic arthritis: systematic review and meta-analysis. RMD Open (2015) 0.77

Anti-TNF Therapy in Ankylosing Spondylitis: Insights for the Clinician. Ther Adv Musculoskelet Dis (2010) 0.77

Treatment efficacy of etanercept and MTX combination therapy for ankylosing spondylitis hip joint lesion in Chinese population. Rheumatol Int (2011) 0.77

The use of tumour necrosis factor alpha-blockers in daily routine. An Austrian consensus project. Clin Rheumatol (2009) 0.77

Spondyloarthritides: evolving therapies. Arthritis Res Ther (2010) 0.77

Safety and clinical responses in ankylosing spondylitis after three months of etanercept therapy. J Korean Med Sci (2008) 0.77

Articles by these authors

Ankylosing spondylitis. Lancet (2007) 6.58

Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res (2010) 6.00

Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res (2013) 5.76

Randomized controlled trial of adalimumab in patients with nonpsoriatic peripheral spondyloarthritis. Arthritis Rheumatol (2015) 4.41

Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial. Lancet (2013) 3.83

Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum (2006) 3.51

A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis (2013) 3.43

Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum (2006) 3.26

Age at disease onset and diagnosis delay in HLA-B27 negative vs. positive patients with ankylosing spondylitis. Rheumatol Int (2002) 2.95

Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis. Arthritis Rheum (2008) 2.75

The challenge of diagnosis and classification in early ankylosing spondylitis: do we need new criteria? Arthritis Rheum (2005) 2.74

Inflammatory back pain in ankylosing spondylitis: a reassessment of the clinical history for application as classification and diagnostic criteria. Arthritis Rheum (2006) 2.67

Non-invasive measurement of brain viscoelasticity using magnetic resonance elastography. NMR Biomed (2008) 2.66

2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis. Ann Rheum Dis (2011) 2.61

The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: a large, randomized, placebo-controlled trial. Arthritis Rheum (2006) 2.54

Symptomatic efficacy of etanercept and its effects on objective signs of inflammation in early nonradiographic axial spondyloarthritis: a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheumatol (2014) 2.52

Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum (2008) 2.48

The early disease stage in axial spondylarthritis: results from the German Spondyloarthritis Inception Cohort. Arthritis Rheum (2009) 2.45

Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores. Ann Rheum Dis (2010) 2.34

The impact of aging and gender on brain viscoelasticity. Neuroimage (2009) 2.15

The concept of axial spondyloarthritis: joint statement of the spondyloarthritis research and treatment network and the Assessment of SpondyloArthritis international Society in response to the US Food and Drug Administration's comments and concerns. Arthritis Rheumatol (2014) 2.14

Critical appraisal of assessment of structural damage in ankylosing spondylitis: implications for treatment outcomes. Arthritis Rheum (2008) 2.14

Effect of non-steroidal anti-inflammatory drugs on radiographic spinal progression in patients with axial spondyloarthritis: results from the German Spondyloarthritis Inception Cohort. Ann Rheum Dis (2012) 2.10

Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial. Ann Rheum Dis (2013) 2.08

Noninvasive assessment of the rheological behavior of human organs using multifrequency MR elastography: a study of brain and liver viscoelasticity. Phys Med Biol (2007) 2.08

Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: results of a twelve-week randomized, double-blind, placebo-controlled trial followed by an open-label extension up to week fifty-two. Arthritis Rheum (2008) 2.04

Major reduction in spinal inflammation in patients with ankylosing spondylitis after treatment with infliximab: results of a multicenter, randomized, double-blind, placebo-controlled magnetic resonance imaging study. Arthritis Rheum (2006) 1.99

MRI inflammation at the vertebral unit only marginally predicts new syndesmophyte formation: a multilevel analysis in patients with ankylosing spondylitis. Ann Rheum Dis (2011) 1.90

Correlation of histopathological findings and magnetic resonance imaging in the spine of patients with ankylosing spondylitis. Arthritis Res Ther (2006) 1.88

Bone loss is detected more frequently in patients with ankylosing spondylitis with syndesmophytes. J Rheumatol (2005) 1.84

Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis. N Engl J Med (2015) 1.83

MR-elastography reveals degradation of tissue integrity in multiple sclerosis. Neuroimage (2009) 1.83

Assessment of liver viscoelasticity using multifrequency MR elastography. Magn Reson Med (2008) 1.80

Down-regulation of the nonspecific and antigen-specific T cell cytokine response in ankylosing spondylitis during treatment with infliximab. Arthritis Rheum (2003) 1.79

Infliximab (REMICADE) therapy in the treatment of pediatric Crohn's disease. Am J Gastroenterol (2003) 1.77

Increased longitudinal growth in rats on a silicon-depleted diet. Bone (2008) 1.75

Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. Ann Rheum Dis (2013) 1.74

Are spondylarthritides related but distinct conditions or a single disease with a heterogeneous phenotype? Arthritis Rheum (2013) 1.69

Clinical vertebral fractures in patients with ankylosing spondylitis. J Rheumatol (2004) 1.68

Similar response rates in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis after 1 year of treatment with etanercept: results from the ESTHER trial. Ann Rheum Dis (2012) 1.68

In vivo viscoelastic properties of the brain in normal pressure hydrocephalus. NMR Biomed (2010) 1.67

Baseline radiographic damage, elevated acute-phase reactant levels, and cigarette smoking status predict spinal radiographic progression in early axial spondylarthritis. Arthritis Rheum (2012) 1.66

Altered skeletal expression of sclerostin and its link to radiographic progression in ankylosing spondylitis. Arthritis Rheum (2009) 1.65

Safety and efficacy of readministration of infliximab after longterm continuous therapy and withdrawal in patients with ankylosing spondylitis. J Rheumatol (2007) 1.63

Analysis of IL-17(+) cells in facet joints of patients with spondyloarthritis suggests that the innate immune pathway might be of greater relevance than the Th17-mediated adaptive immune response. Arthritis Res Ther (2011) 1.61

Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab. Arthritis Res Ther (2005) 1.61

The human anti-IL-1 beta monoclonal antibody ACZ885 is effective in joint inflammation models in mice and in a proof-of-concept study in patients with rheumatoid arthritis. Arthritis Res Ther (2008) 1.60

Consensus on a core set of domains for psoriatic arthritis. J Rheumatol (2007) 1.60

Effectiveness, safety, and predictors of good clinical response in 1250 patients treated with adalimumab for active ankylosing spondylitis. J Rheumatol (2009) 1.58

Concepts and epidemiology of spondyloarthritis. Best Pract Res Clin Rheumatol (2006) 1.57

The relationship between inflammation and new bone formation in patients with ankylosing spondylitis. Arthritis Res Ther (2008) 1.56

HLA-B27-restricted CD8+ T cell response to cartilage-derived self peptides in ankylosing spondylitis. Arthritis Rheum (2005) 1.55

Association of baseline levels of markers of bone and cartilage degradation with long-term progression of joint damage in patients with early rheumatoid arthritis: the COBRA study. Arthritis Rheum (2002) 1.55

The place of juvenile onset spondyloarthropathies in the Durban 1997 ILAR classification criteria of juvenile idiopathic arthritis. International League of Associations for Rheumatology. J Rheumatol (2002) 1.55

Stapled transanal rectal resection vs. transvaginal rectocele repair for treatment of obstructive defecation syndrome. Dis Colon Rectum (2009) 1.52

TNF signaling drives myeloid-derived suppressor cell accumulation. J Clin Invest (2012) 1.52

Fractional encoding of harmonic motions in MR elastography. Magn Reson Med (2007) 1.49

MR elastography of the human heart: noninvasive assessment of myocardial elasticity changes by shear wave amplitude variations. Magn Reson Med (2009) 1.47

Population pharmacokinetics of infliximab in patients with ankylosing spondylitis. J Clin Pharmacol (2008) 1.43

Both structural damage and inflammation of the spine contribute to impairment of spinal mobility in patients with ankylosing spondylitis. Ann Rheum Dis (2010) 1.43

High prevalence of morphometric vertebral deformities in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol (2008) 1.43

Making an impact on mortality in rheumatoid arthritis: targeting cardiovascular comorbidity. Arthritis Rheum (2004) 1.42

Brain viscoelasticity alteration in chronic-progressive multiple sclerosis. PLoS One (2012) 1.41

Quantitation of simulated short echo time 1H human brain spectra by LCModel and AMARES. Magn Reson Med (2004) 1.41

Vertebral erosions associated with spinal inflammation in patients with ankylosing spondylitis identified by magnetic resonance imaging: changes after 2 years of tumor necrosis factor inhibitor therapy. J Rheumatol (2013) 1.41

Relationship between changes in BMD and nonvertebral fracture incidence associated with risedronate: reduction in risk of nonvertebral fracture is not related to change in BMD. J Bone Miner Res (2005) 1.39

Immunohistologic analysis of zygapophyseal joints in patients with ankylosing spondylitis. Arthritis Rheum (2006) 1.38

Double-blinded infliximab dose escalation in patients with rheumatoid arthritis. Ann Rheum Dis (2007) 1.37

In vivo determination of hepatic stiffness using steady-state free precession magnetic resonance elastography. Invest Radiol (2006) 1.35

Identification of the most common problems by patients with ankylosing spondylitis using the international classification of functioning, disability and health. J Rheumatol (2006) 1.35

Predicting the outcome of ankylosing spondylitis therapy. Ann Rheum Dis (2011) 1.35

Performance of referral recommendations in patients with chronic back pain and suspected axial spondyloarthritis. Ann Rheum Dis (2007) 1.34

Do patients with non-radiographic axial spondylarthritis differ from patients with ankylosing spondylitis? Arthritis Care Res (Hoboken) (2012) 1.34

Rates and predictors of radiographic sacroiliitis progression over 2 years in patients with axial spondyloarthritis. Ann Rheum Dis (2011) 1.33

ASAS recommendations for collecting, analysing and reporting NSAID intake in clinical trials/epidemiological studies in axial spondyloarthritis. Ann Rheum Dis (2010) 1.30

Descriptions of spinal MRI lesions and definition of a positive MRI of the spine in axial spondyloarthritis: a consensual approach by the ASAS/OMERACT MRI study group. Ann Rheum Dis (2012) 1.30

Shear wave group velocity inversion in MR elastography of human skeletal muscle. Magn Reson Med (2006) 1.29

Viscoelasticity-based MR elastography of skeletal muscle. Phys Med Biol (2010) 1.29